文献速递免疫规划

疫苗微针阵列贴片自我接种:50岁及以上成人的初步研究

Vaccine microarray patch self-administration: A preliminary study in adults 50 years of age and over.
PubMed 文献 · Vaccine · 2025-01-30

本研究在澳大利亚布里斯班开展单中心、开放标签、单臂干预,评估高密度微针阵列贴片(HD-MAP)在50岁及以上健康成人中的安全性、性能、可接受性和可用性。HD-MAP耐受良好,无治疗相关严重不良事件;自我接种与培训人员接种的皮肤反应相似,所有参与者认为接种器易用,82%若疗效等效于肌内注射则偏好HD-MAP接种,98%认为居家无监督自我接种高度可取。

要点

  • HD-MAP在50岁及以上成人中耐受良好,无治疗相关严重不良事件。
  • 自我接种与培训人员接种后的经表皮水分丢失增加及荧光皮肤镜表现相似。
  • 所有参与者认为HD-MAP接种器易用,82%偏好HD-MAP接种(若疗效等效于肌内注射)。

核心结论

  • HD-MAP在50岁及以上成人中安全,无论接种者是谁性能均有效。
  • 参与者因易用性和自我接种便利性而偏好HD-MAP。
  • 这种疫苗递送方法在该人群中显示出未来实施的希望。

研究设计与样本

  • 单中心、开放标签、单臂干预研究,纳入50岁及以上健康成人。
  • HD-MAP(无疫苗)由培训人员接种和自我接种,比较前臂掌侧和上臂应用部位的皮肤反应。
  • 参与者完成在线调查和半结构化访谈,分析采用描述性统计,访谈用NVivo 12编码并做主题分析。
  • 研究于2021年9月8日至2022年2月15日在澳大利亚布里斯班进行。

主要发现

  • 44名参与者中,43%(n=19)为男性,57%(n=25)为女性。
  • HD-MAP耐受良好,无治疗相关严重不良事件。
  • 自我接种后经表皮水分丢失增加与培训人员接种相似(上臂:7.5倍 vs 6倍,前臂:6.1倍 vs 6.6倍)。
  • 荧光皮肤镜确认HD-MAP与皮肤表面接触,自我接种与培训人员接种相似。
  • 所有参与者认为HD-MAP接种器易用;82%的参与者在疗效被证明等效于肌内注射时偏好HD-MAP接种;82%的参与者对皮肤上短暂痕迹高度接受;98%的参与者同意居家无监督自我接种HD-MAP因其便利性而高度可取。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: We assessed the safety, performance, acceptability, and usability of the High-Density Microarray Patch (HD-MAP) for vaccination in adults aged 50 and over. METHODS: This study was a single-centre, open-label, single-arm intervention in healthy adults aged 50+. HD-MAPs (vaccine-free) were applied by a trained user and self-administered. Participants received one excipient-coated HD-MAP to the volar forearm (FA) and the upper arm (UA) administered by a trained user. Participants then self-administered a HD-MAP to the FA and UA. Application sites were compared for skin response. Participants completed an online survey and participated in a semi-structured interview on acceptability and usability. Analyses were undertaken using descriptive statistics. Interviews were coded in NVivo 12 and subject to thematic analysis. The study occurred from 8 September 2021 to 15 February 2022 in Brisbane, Australia. RESULTS: Of 44 participants, 43 % (n = 19) were male, and 57 % (n = 25) female. The HD-MAP was well-tolerated, with no treatment-related serious adverse events. The increase in transepidermal water loss following self-administration was similar to that observed for trained user administration (UA: 7.5 fold vs 6-fold, FA: 6.1-fold vs 6.6 fold). Fluorescent dermatoscopy confirmed that HD-MAPs engaged with the skin surface and that self and trained user administrations were similar. All participants found the HD-MAP applicator easy to use. 82 % of participants preferred "vaccination" by HD-MAP should its efficacy be proven equivalent to intramuscular injection (IM). Participants reported high acceptance of the resulting transient marks on the skin (82 %). 98 % of participants agreed that self-administration of the HD-MAP at home, without supervision, was highly preferable for its convenience. CONCLUSION: HD-MAPs were safe in adults 50+ years, and performance was effective, regardless of administrator. Participants preferred the HD-MAP for its ease of use and convenience in self-administration. This vaccine delivery method shows promise for future implementation for this population.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Davies C, Baker B, Berger MN, et al. Vaccine microarray patch self-administration: A preliminary study in adults 50 years of age and over. Vaccine. 2025. PMID: 39890558. doi:10.1016/j.vaccine.2024.126699

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。